Core Viewpoint - Philip Morris International (PMI) is transitioning towards a smoke-free future by diversifying its product portfolio beyond traditional tobacco and nicotine products, focusing on innovative smoke-free alternatives [1] Product Portfolio - PMI's current offerings include cigarettes and smoke-free products such as heat-not-burn, nicotine pouches, and e-vapor products [1] - As of June 30, 2025, PMI estimates that over 41 million legal-age consumers globally are using its smoke-free products, many of whom have reduced or stopped cigarette consumption [1] - The smoke-free segment contributed to 41% of PMI's total net revenues in the first nine months of 2025 [1] Investment and Development - Since 2008, PMI has invested over $14 billion in the development and commercialization of smoke-free products aimed at adult smokers [1] - The company has established scientific assessment capabilities in areas such as pre-clinical systems toxicology, clinical and behavioral research, and post-market studies [1] Regulatory Approvals - The U.S. Food and Drug Administration (FDA) has authorized the marketing of Swedish Match's General snus and ZYN nicotine pouches, as well as versions of PMI's IQOS devices and consumables, marking the first-ever authorizations in their categories [1] - IQOS devices and General snus have also received the first-ever Modified Risk Tobacco Product authorizations from the FDA [1] Future Ambitions - PMI aims to leverage its expertise in life sciences to expand into wellness and healthcare sectors, focusing on enhancing life through seamless health experiences [1]

Core Insights - Philip Morris International Inc. (PMI) has released a white paper titled "Human Cognition: The Next Frontier?" which discusses the evolving role of human cognition in the context of artificial intelligence transforming work, society, and the economy [1][2]. Company Strategy - PMI emphasizes that human capabilities such as critical thinking, creativity, and adaptability will become essential "superskills" in an era of human-machine collaboration, as AI automates routine tasks [2]. - The company is committed to a smoke-free future, with smoke-free products accounting for 41% of its net revenues as of June 30, 2025, and aims to be predominantly smoke-free by 2030 [3][4][5]. Investment and Development - Since 2008, PMI has invested over $14 billion in developing and commercializing innovative smoke-free products, aiming to end cigarette sales entirely [5]. - The company has established world-class scientific assessment capabilities in various research areas, including pre-clinical systems toxicology and clinical research [7]. Cognitive Risks - The white paper outlines several cognitive risks associated with AI, including cognitive atrophy, attention erosion, the emerging cognitive divide, and trust and verification challenges [6]. - Cognitive atrophy refers to the risk of losing deep thinking and originality as AI automates more cognitive tasks [6]. - Attention erosion is caused by a digital environment that fragments focus, undermining decision quality and critical reasoning [6]. - The cognitive divide highlights the risk of unequal access to advanced learning and cognitive resources, potentially leading to socioeconomic disparities [6]. - Trust and verification challenges arise from the proliferation of synthetic media, necessitating new skills for information verification [6].

Core Insights - The survey indicates strong global support for smoke-free alternatives to cigarettes, with 78% of respondents agreeing that adult smokers should have access to better options [2][3] - There is significant concern (76%) that public health decisions are influenced more by ideology than by scientific evidence [3][6] - Countries that adopt smoke-free products have experienced declines in cigarette sales and smoking rates, highlighting the demand for evidence-based policies [4] Group 1: Public Support for Smoke-Free Alternatives - 80% of adults believe that smokers should have access to smoke-free options [1] - 74% of respondents think that encouraging smokers to switch to these products can improve public health [2] - 78% of respondents want their governments to consider scientific evidence regarding smoke-free alternatives before imposing restrictions [3] Group 2: Concerns Over Public Health Policies - 76% of respondents are concerned that decisions are made based on ideology rather than science [3][6] - 58% agree that it is wrong for governments to ban less harmful alternatives while allowing cigarette sales [6] - 61% believe it is a public health failure that 29% of the global adult population lives in countries where smoke-free alternatives are banned [6] Group 3: Market Access and Regulatory Environment - Over 190 million smokers in more than 20 countries lack legal access to smoke-free products, despite the availability of harmful cigarettes [5] - 82% of legal-age smokers in countries with bans on smoke-free products want the opportunity to purchase them legally [6] - The survey highlights a strong desire for governments to adopt policies that align with scientific findings, particularly in countries with existing bans [3][6] Group 4: Company Position and Investment - Philip Morris International has invested over $14 billion since 2008 in developing smoke-free products, aiming to end cigarette sales [8] - As of June 30, 2025, smoke-free products accounted for 41% of PMI's total net revenues [8] - PMI's smoke-free products are available in 97 markets, with over 41 million legal-age consumers using them [8]